pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,914 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1183Endpoints900BioPharma Dive347BioSpace317Fierce Biotech301onclive165raps106globenewswire health
therapy area
allOncology7746Rare Disease1884Cardiology1758Immunology1504Hematology1327Vaccines1204Pulmonology
  • STAT chooses to keep health care as two words despite AP stylebook shift
    The Associated Press updated its style guide in April, merging health care into the single word healthcare. The change sparked discussion among journalists and readers. At STAT, the editorial staf…
    STAT · 3mo agoNeutral↗ source
  • J&J to buy Firefly Bio for $1 billion to boost KRAS inhibitor program
    J&J announced Monday it will acquire biotech startup Firefly Bio for $1 billion, aiming to broaden its KRAS inhibitor portfolio. The move follows recent data from Revolution Medicines showing a KR…
    STAT · 3mo agoDealPositive↗ source
← prev
page 55 of 77
next →
73
fda recalls70
fda medwatch60
fda press38
1200
Psychiatry & CNS868
Ophthalmology502
Pain482
Endocrinology & Metabolism481
Infectious Disease444
  • Financing gaps keep $2 million gene therapies out of reach for many patients
    William Padula argues that the United States lacks the financial infrastructure to deliver ultra‑expensive gene therapies, even though they can cure diseases with a single dose. He notes that treat…
    STAT · 3mo agoNegative↗ source
  • Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer results
    Lilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
    STAT · 3mo agoPositive readoutPositive↗ source
  • AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trial
    A Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Congo Ebola frontline health workers face low pay and exhaustion amid outbreak
    Dr. Richard Lokudu, medical director of Mongbwalu General Referral Hospital, says he and his colleagues are receiving almost no compensation while treating patients in the current Ebola outbreak.…
    STAT · 3mo agoNegative↗ source
  • Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisition
    Novo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…
    STAT · 3mo agoNeutral↗ source
  • Tango and Revolution report high response rates in early pancreatic cancer combo trial
    Tango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…
    STAT · 3mo agoPositive readoutPositive↗ source
  • UnitedHealthcare reduces reimbursement for lactation counseling, sparking provider backlash
    UnitedHealthcare announced a change to its payment policy for lactation counseling services. The new policy would lower or eliminate reimbursement for many providers who offer these services, prom…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Mass General launches mobile vascular clinic to treat unhoused patients and prevent amputations
    Unhoused individuals often face untreated vascular problems that can quickly lead to severe wounds and the risk of losing a limb. Limited access to regular medical care leaves many without timely i…
    STAT · 3mo agoPositive↗ source
  • ADA conference sees data presentations and police escort of members over editorial distribution
    The American Diabetes Association held its annual meeting in New Orleans, concluding three days of sessions that featured new data readouts and scientific presentations. Attendees heard updates on…
    STAT · 3mo agoNeutral↗ source
  • U.S. horses face obesity epidemic mirroring human rates
    A recent peer‑reviewed study found that about 51% of mature light‑breed horses in the United States are obese, a prevalence that ranks among the world’s highest and exceeds rates in Britain, Austra…
    STAT · 3mo agoNegative↗ source
  • Boehringer’s obesity drug cuts liver fat but lags behind competitors in weight loss
    Data from a Phase 3 trial of Boehringer Ingelheim’s weekly injectable survodutide were presented at the American Diabetes Association meeting. Patients receiving the highest dose lost about 13% of…
    STAT · 3mo agoNegative readoutNegative↗ source
  • STAT roundup highlights obesity drug competition and other ADA conference updates
    STAT's ADA in 30 Seconds newsletter offers a brief snapshot of the American Diabetes Association's annual meeting, covering a range of topics for readers. Elaine Chen notes that the market for obe…
    STAT · 3mo agoNeutral↗ source
  • Lilly presents safety data on obesity drug retatrutide, noting rare cardiac events
    Eli Lilly reported new safety and tolerability findings for its next-generation obesity therapy retatrutide at the American Diabetes Association annual meeting. In the study, 7 of the 403 particip…
    STAT · 3mo agoNegative readoutNeutral↗ source
  • Pfizer’s monthly obesity drug berobenatide shows up to 12% weight loss in mid-stage VESPER-3 study
    Detailed data from Pfizer's mid‑stage VESPER-3 trial indicate that the company’s monthly‑dosed obesity candidate, berobenatide, continues to demonstrate weight‑loss potential. The drug, originally…
    STAT · 3mo agoPositive readoutNeutral↗ source
  • Former CDC director warns that new Ebola outbreak in DRC requires massive, immediate action
    Tom Frieden, who led the U.S. CDC response to the 2014‑2016 West Africa Ebola epidemic that killed more than 11,000 people, writes about the new crisis in the Democratic Republic of the Congo. He…
    STAT · 3mo agoNegative↗ source
  • ADA conference spotlights triple hormone receptors, a monthly obesity drug and mixed outcomes
    The American Diabetes Association’s annual meeting in New Orleans featured updates on emerging diabetes therapies. Speakers highlighted research on drugs that target three hormone receptors simulta…
    STAT · 3mo agoNeutral↗ source
  • Growing Amish population poses unique public health challenges, says STAT opinion piece
    The First Opinion podcast explored how the expanding Amish community impacts public health, noting that the group may approach 2 million people in the United States by 2075. While some political fi…
    STAT · 3mo agoNeutral↗ source
  • CDC warns Ebola could swell to 20,000 cases in Central Africa without rapid containment
    The U.S. Centers for Disease Control and Prevention released a new analysis indicating that the Ebola outbreak in Central Africa could expand to as many as 20,000 cases if infected individuals are…
    STAT · 3mo agoNegative↗ source
  • HHS reclassifies 8,000 staff under Schedule F, easing firing rules and raising political pressure
    An executive order issued in late June reclassified roughly 8,000 employees of the Department of Health and Human Services. The change moves them into a “Schedule F” category that removes many civi…
    STAT · 3mo agoRegulatoryNegative↗ source
  • HHS Office of Human Research Protections faces staff shortages, jeopardizing participant safety oversight
    In 2021 the Office of Human Research Protections (OHRP) received a report of a participant suicide during a depression and mobility study at the New York State Psychiatric Institute. The incident p…
    STAT · 3mo agoRegulatoryNegative↗ source
  • ADA conference preview spotlights newer GLP-1 drugs, research funding cuts and a protest
    Elizabeth Cooney reports from the American Diabetes Association annual meeting in New Orleans, introducing the first of three STAT "ADA in 30 Seconds" newsletters. She notes the warm weather outsid…
    STAT · 3mo agoNeutral↗ source
  • US shifts Ebola treatment for exposed Americans to overseas facilities, sparking concerns over care access
    In an opinion piece, infectious‑disease physician Krutika Kuppalli reflects on her experience responding to the West Africa Ebola outbreak and the expectations that the United States would bring il…
    STAT · 3mo agoRegulatoryNegative↗ source
  • NIH senior adviser promotes MAHA strategy at ADA conference amid skeptical audience
    At the American Diabetes Association meeting in New Orleans, Richard Woychik, a senior adviser to NIH Director Jay Bhattacharya, opened his remarks by endorsing the Make America Healthy Again (MAHA…
    STAT · 3mo agoNeutral↗ source